ReNeuron
Type | Public company |
---|---|
LSE: RENE | |
Industry | Stem cell research & development |
Founded | 1997 |
Headquarters | Surrey, England, UK |
Key people | chairman = Trevor Jones |
Website | reneuron.com |
ReNeuron is a UK-based stem cell research company whose shares are listed on the Alternative Investment Market. Its focus is on the development of stem-cell therapies targeting areas of poorly-met medical need, including peripheral arterial disease, strokes, and retinal diseases.
ReNeuron is testing the effects of neural stem cells on spinal cords for neuroregeneration.[1] They are also testing the use of fetal stem cells on stroke patients.[2]
References[]
- ^ Cookson, Clive (4 May 2010). "Regenerative medicine: Possibilities multiply for nerve cell regrowth". Retrieved 23 May 2010.
- ^ "EU agency prepares to assess first stem cell drug". Reuters. 12 May 2010. Retrieved 23 May 2010.
External links[]
Categories:
- Biotechnology companies of the United Kingdom
- Biotechnology companies established in 1997
- 1997 establishments in the United Kingdom
- United Kingdom company stubs